Figures for Zhang et al., 2017



Figure Caption/Comments:

Fig. 7

Erk Inhibition Cooperates with CBL0137 to Suppress MYCN;Gab2wt Neuroblastoma

(A–F) EGFP-expressing tumors (arrowhead) in the MYCN;Gab2wt transgenic fish treated with vehicle (A and B), CBL0137 alone (C and D), or CBL0137 plus trametinib (E and F) at day 1 or day 15 of treatment. Scale bar, 1 mm.

(G) Differences in tumor volume in animals treated with vehicle, CBL0137, or CBL0137 plus trametinib on day 15 versus day 1, as measured by the size of EGFP-positive tumor masses using ImageJ software. Mean values (horizontal bars) were compared by Welch t test (two-tailed).

(H) Histopathologic and immunohistochemical analyses of MYCN;Gab2wt tumors treated with vehicle or combined CBL0137 and trametinib. Left: H&E-stained sagittal sections. Right: immunohistochemical staining with PCNA antibody. Scale bar, 50 μm.

(I) Immunoblot of lysates from MYCN;Gab2wt tumors treated with vehicle or CBL0137 and trametinib. Total levels of Erk1/2 serve as loading controls.

See also Figures S5 and S6.

Figure Data:
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image.